AKBA Akebia Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AKBA

Price (delayed)

$1.325

Market cap

$277.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.28

Enterprise value

$278.12M

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is ...

Highlights
AKBA's debt has dropped by 54% year-on-year and by 17% since the previous quarter
Akebia Therapeutics's EPS has increased by 46% YoY and by 13% from the previous quarter
AKBA's gross profit is down by 42% year-on-year and by 16% since the previous quarter
Akebia Therapeutics's revenue has decreased by 33% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://akebia.com
Peers: JNJ NVS AMGN NKTR

Key stats

What are the main financial stats of AKBA
Market
Shares outstanding
209.37M
Market cap
$277.42M
Enterprise value
$278.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.43
Earnings
Revenue
$194.62M
EBIT
-$45.89M
EBITDA
-$4.05M
Free cash flow
-$23.38M
Per share
EPS
-$0.28
Free cash flow per share
-$0.12
Book value per share
-$0.16
Revenue per share
$1.04
TBVPS
$0.78
Balance sheet
Total assets
$241.7M
Total liabilities
$272.29M
Debt
$43.63M
Equity
-$30.58M
Working capital
$18.28M
Liquidity
Debt to equity
-1.43
Current ratio
1.18
Quick ratio
0.82
Net debt/EBITDA
-0.17
Margins
EBITDA margin
-2.1%
Gross margin
61.9%
Net margin
-26.7%
Operating margin
-22.1%
Efficiency
Return on assets
-20.6%
Return on equity
N/A
Return on invested capital
-73.3%
Return on capital employed
-32.4%
Return on sales
-23.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKBA stock price

How has the Akebia Therapeutics stock price performed over time
Intraday
-0.38%
1 week
-2.57%
1 month
-33.75%
1 year
67.09%
YTD
6.85%
QTD
-27.6%

Financial performance

How have Akebia Therapeutics's revenue and profit performed over time
Revenue
$194.62M
Gross profit
$120.47M
Operating income
-$43.02M
Net income
-$51.93M
Gross margin
61.9%
Net margin
-26.7%
AKBA's net income is up by 45% YoY and by 10% from the previous quarter
The operating income is up by 45% year-on-year and by 12% since the previous quarter
AKBA's gross profit is down by 42% year-on-year and by 16% since the previous quarter
Akebia Therapeutics's revenue has decreased by 33% YoY

Growth

What is Akebia Therapeutics's growth rate over time

Valuation

What is Akebia Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.43
Akebia Therapeutics's EPS has increased by 46% YoY and by 13% from the previous quarter
The equity is up by 22% since the previous quarter
The price to sales (P/S) is 42% more than the last 4 quarters average of 0.9 but 20% less than the 5-year quarterly average of 1.6
Akebia Therapeutics's revenue has decreased by 33% YoY

Efficiency

How efficient is Akebia Therapeutics business performance
Akebia Therapeutics's ROS has increased by 12% YoY and by 11% from the previous quarter
The return on invested capital is up by 12% year-on-year but it has declined by 7% since the previous quarter

Dividends

What is AKBA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKBA.

Financial health

How did Akebia Therapeutics financials performed over time
AKBA's total assets is 11% smaller than its total liabilities
AKBA's total assets is down by 32% year-on-year but it is up by 2.9% since the previous quarter
The total liabilities has contracted by 22% YoY
The debt to equity has dropped by 108% year-on-year and by 7% since the previous quarter
AKBA's debt has dropped by 54% year-on-year and by 17% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.